Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.
Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy. On March 27, 2020, durvalumab was approved by the FDA for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Durvalumab is indicated for the treatment of adults with the following conditions:
Research Site, Pamplona, Spain
Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong
The University of Hong Kong, Hong Kong, Hong Kong
Shanghai Chest Hospital, Shanghai, Shanghai, China
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Research Site, Hue, Vietnam
New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
Weill Cornell Medicine, New York, New York, United States
New York-Presbyterian Queens, Flushing, New York, United States
Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
M D Anderson Cancer Center, Houston, Texas, United States
The Jewish General Hospital, Montreal, Quebec, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
Odette Cancer Centre, Toronto, Ontario, Canada
Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.